We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Reata Pharmaceuticals Inc | NASDAQ:RETA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 172.36 | 189.75 | 172.36 | 0 | 01:00:00 |
From May 2023 to May 2024
By Robb M. Stewart
Reata Pharmaceuticals' shares look set for a strong open Wednesday after the biopharmaceutical company received regulatory approval to offer its drug for the treatment of Friedreich's ataxia in the U.S.
In premarket trading, the shares were 12% higher after ending the previous session at $92.39.
Reata after the market closed Tuesday said the U.S. Food and Drug Administration approved the prior-approval supplement to update the drug substance specification for Skyclarys.
Skyclarys is the first and only FDA-approved drug for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. With this approval, the drug is now available to patients with Friedreich's ataxia in the U.S., Reata said.
Friedreich's ataxia is an ultra-rare, genetic, life-shortening, debilitating and degenerative neuromuscular disorder.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 28, 2023 07:05 ET (11:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Reata Pharmaceuticals Chart |
1 Month Reata Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
